ALE.C04

News alerts, weekly reports and conference planners

Company:

Alentis Therap

Drug class:

CLDN1 inhibitor

‹

›

CLDN1 positive	Squamous Cell Carcinoma of Head and Neck	CLDN1 positive	Squamous Cell Carcinoma of Head and Neck	ALE.C04 Sensitive: B - Late Trials ALE.C04 Sensitive : B	ALE.C04 Sensitive: B - Late Trials ALE.C04 Sensitive : B
CLDN1 overexpression	Solid Tumor	CLDN1 overexpression	Solid Tumor	ALE.C04 Sensitive: D – Preclinical ALE.C04 Sensitive : D	ALE.C04 Sensitive: D – Preclinical ALE.C04 Sensitive : D

Associations
(2)